Results 41 to 50 of about 526 (152)

Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. [PDF]

CNS Drugs
Background and objectivesResidual sleepiness can occur in adult patients with obstructive sleep apnea (OSA) despite adequate treatment with continuous positive airway pressure (CPAP).
Tanayapong P, Tantrakul V, Liamsombut S, Siriyotha S, McKay G, Attia J, Thakkinstian A.   +6 more
europepmc   +2 more sources

Is obstructive sleep apnea a circadian rhythm disorder?

Journal of Sleep Research, Volume 32, Issue 4, August 2023., 2023
Summary Obstructive sleep apnea is the most common sleep‐related breathing disorder worldwide and remains underdiagnosed. Its multiple associated comorbidities contribute to a decreased quality of life and work performance as well as an increased risk of death.
Julija Šmon, Eva Kočar, Tadeja Pintar, Leja Dolenc‐Grošelj, Damjana Rozman   +4 more
wiley   +1 more source

Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels

Clinical Pharmacology &Therapeutics, Volume 113, Issue 2, Page 226-245, February 2023., 2023
This review presents a European Federation of Pharmaceutical Industries and Association/PreClinical Development Expert Group (EFPIA‐PDEG) topic group consensus on a data‐driven approach to harmonized contraception recommendations for clinical trial protocols and product labeling.
Christopher J. Bowman, Nathalie Becourt‐Lhote, Virginie Boulifard, Rüdiger Cordts, Solange Corriol‐Rohou, Brian Enright, Linda Erkman, Jayne Harris, Andreas Hartmann, Jan Hilpert, Sophie Kervyn, Britta Mattson, LaRonda Morford, Mireille Muller, Marcy Powell, Zhanna Sobol, Rajamuthu Srinivasan, Claudia Stark, Kary E. Thompson, Katie J. Turner, Paul Barrow   +20 more
wiley   +1 more source

Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. [PDF]

, 2021
STUDY OBJECTIVES: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union to treat excessive daytime sleepiness in patients with obstructive sleep apnea (OSA) (37.5-150 mg/day) and narcolepsy (75 ...
Mayer, Geert, Schweitzer, Paula K, Rosenberg, Russell, Strohl, Kingman P, Chandler, Patricia, Baladi, Michelle, Lee, Lawrence, Malhotra, Atul   +7 more
core   +1 more source

1269 Off-Label Use of Solriamfetol In Idiopathic Hypersomnia [PDF]

Sleep, 2020
Abstract Introduction Solriamfetol is a new daily dopamine and norepinephrine reuptake inhibitor indicated for improving daytime wakefulness in adults with obstructive sleep apnea (OSA) and narcolepsy. It was FDA-approved on 3/20/2019.
Talha Memon, Tammy Wong
openaire   +1 more source

Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy [PDF]

, 2022
STUDY OBJECTIVES: This post hoc analysis characterized the weekly incidence and overall duration of common early-onset, treatment-emergent adverse events (TEAEs) during solriamfetol treatment. METHODS: Participants (obstructive sleep apnea [OSA], n = 474;
Schweitzer, Paula, Dauvilliers, Yves, Thorpy, Michael J., Schweitzer, Paula K, Gotfried, Mark, Zammit, Gary, Malhotra, Atul, Thorpy, Michael, Rosenberg, Russell, Schweitzer, Paula K., Thorpy, Michael J, Bujanover, Shay, Scheckner, Brian   +12 more
core   +1 more source

0673 Effects Of Solriamfetol On Driving Performance In Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea

, 2020
Introduction Excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA) is associated with an increased risk of driving accidents.
Vermeeren, A., Vinckenbosch, F., Asin, J., Wang, G., Zhou, K., Vonk, P., Lammers, G., Carter, L., Ramaekers, J., Donjacour, C., De Vries, N., Janssen, H., Overeem, S., Chen, D.   +13 more
core   +1 more source

Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial [PDF]

, 2020
Background: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, improved wakefulness and reduced excessive daytime sleepiness (EDS) in studies of participants with narcolepsy with and without cataplexy.
Mayer, G., Mayer G., Dauvilliers, Yves, Shapiro, Colin, Thorpy M. J., Thorpy, M.J., Black, Jed, Dauvilliers, Y., Emsellem, H., Thorpy, Michael, Shapiro, C., Carter, L.P., Lee, L., Mayer, Geert, Lammers, Gert Jan, Plazzi G., Plazzi, G., Lee, Lawrence, Black J., Chen, Dan, Dauvilliers Y., Shapiro C., Chen D., Lammers G. J., Plazzi, Giuseppe, Emsellem H., Carter L. P., Lammers, G.J., Carter, Lawrence, Emsellem, Helene, Lee L., Chen, D., Black, J.   +32 more
core   +1 more source

Recent advances in treatment for narcolepsy

Therapeutic Advances in Neurological Disorders, 2019
Narcolepsy type 1 (NT1) is a chronic orphan disorder, caused by the selective and irreversible loss of hypocretin/orexin (ORX) neurons, by a probable autoimmune process.
Lucie Barateau, Yves Dauvilliers
doaj   +1 more source

Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns

Nature and Science of Sleep, 2020
Emily C Barker,1 Julie Flygare,2 Shalini Paruthi,3,4 Katherine M Sharkey5– 7 1Case Western Reserve University School of Medicine, Department of Pediatrics, Cleveland, OH, USA; 2Project Sleep, Los Angeles, CA, USA; 3Sleep Medicine and Research ...
Barker EC, Flygare J, Paruthi S, Sharkey KM   +3 more
doaj